• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Microbot Medical Inc.

    7/29/25 1:55:17 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MBOT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Microbot Medical Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    59503A204

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    59503A204


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,030,667.00
    8Shared Dispositive Power

    19,971.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,050,638.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.63 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Microbot Medical Inc
    (b)Address of issuer's principal executive offices:

    175 Derby Street, Suite 27/1, Hingham, MA, 02043
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    59503A204
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2050638
    (b)Percent of class:

    5.63  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2030667

     (iv) Shared power to dispose or to direct the disposition of:

    19971

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $MBOT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MBOT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications

    With the Newly Granted IP, the Company's IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending. The Company Continues to Scale Commercial Readiness Plans for the LIBERTY® System as it Awaits FDA Decision. HINGHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company a patent, covering a modular robotic surgical system which includes a base and a plurality of tool-receiver units arranged as separate units and independently and interchangeably a

    8/20/25 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

    NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors. Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financia

    8/8/25 8:00:00 AM ET
    $DHAI
    $MBOT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Microbot Medical® Receives Non-Dilutive Grant to Enhance Operational Capabilities

    HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced it has been approved to receive a non-dilutive grant from the Israel Innovation Authority ("IIA") in the amount of NIS 2.15 Million (approximately $630,000 at a recent exchange rate). The funding will further strengthen the Company's manufacturing capabilities, positioning it to successfully implement the commercialization of the LIBERTY® System, pending marketing clearance by the U.S. Food and Drug Administration (FDA). In addition to recognizing the Company's recent milestone achievements, the IIA acknowledged several other fa

    8/5/25 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MBOT
    SEC Filings

    View All

    Microbot Medical Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    8/25/25 4:15:46 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Microbot Medical Inc. (0000883975) (Filer)

    8/20/25 8:30:28 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Microbot Medical Inc.

    10-Q - Microbot Medical Inc. (0000883975) (Filer)

    8/12/25 4:30:48 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by General Manager, CTO Sharon Simon

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    2/7/25 4:30:14 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Diaz-Cartelle Juan

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    2/7/25 4:30:13 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Vaknin Rachel

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    2/7/25 4:30:17 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MBOT
    Leadership Updates

    Live Leadership Updates

    View All

    DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

    NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors. Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financia

    8/8/25 8:00:00 AM ET
    $DHAI
    $MBOT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Microbot Medical® Expands Commercial Leadership with Appointment of Christina Bailey as VP of Sales

    HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals.  She will report directly to Harel Gadot, the Company's CEO, President and Chairman. Ms. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and

    7/22/25 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System

    Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year This Appointment Represents the Company's First Commercial Hire as it Ramps Up Commercial Readiness in Anticipation of FDA Clearance during the Second Quarter of 2025 BRAINTREE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Paul Mullen, a seasoned medical device sales expert in the Endovascular space, to the newly created role of Vice President of Sales. Mr. Mullen has an extensive track record in sales, market developm

    3/4/25 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Microbot Medical Inc. (Amendment)

    SC 13G/A - Microbot Medical Inc. (0000883975) (Subject)

    2/14/24 2:49:35 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Microbot Medical Inc.

    SC 13G - Microbot Medical Inc. (0000883975) (Subject)

    2/14/23 1:04:05 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care